Psychedelics – News and Features

News
Study Supports Psilocybin’s Potential To Treat Depressive Symptoms
Study suggests that high doses of psilocybin appears to have a similar effect on depressive symptoms as the selective serotonin reuptake inhibitor escitalopram.

Industry Insight
After MDMA’s FDA Approval Setback, Science Must Lead the Way
Dr. Sergio Pérez Rosal explains why, in his opinion, “hope is not lost” and the therapeutic potential of psychedelics for the treatment of psychiatric disorders could still be unlocked. But what happens next must be firmly rooted in science.

News
MDMA-Assisted PTSD Therapy Rejected by FDA
The US Food and Drug Administration (FDA) has rejected the use of MDMA-assisted therapy for post-traumatic stress disorder (PTSD), according to an announcement from the therapy’s drugmaker, Lykos Therapeutics.

News
Understanding Ketamine’s Brain-Specific Actions Could Lead to Better Antidepressants
Researchers from Zhejiang University have uncovered the mechanistic basis behind ketamine’s rapid antidepressant effects. Published in Science, this study holds significant promise for developing more effective antidepressant treatments.

News
Rapid Tagging Method Reveals Psychedelics' Immediate Effects on Neurons
Neuron-tagging method developed by researchers at UC Davis reveals how psychedelic compounds impact individual neurons in the brain.

News
Psychedelic Trips From Psilocybin a Result of Disruptions to the Brain Network
In a new study, researchers report that psilocybin, the active compound in magic mushrooms, temporarily scrambles a critical network of brain areas involved in introspective thinking such as daydreaming and remembering.

News
Immune Cell Inflammation Responsible for Severe Symptoms in Rare Neurodegenerative Disease
Researchers at The Hospital for Sick Children (SickKids) have found that inflammation in an immune cell may be responsible in part for some severe symptoms in a group of rare genetic conditions called lysosomal storage diseases (LSDs).

News
Mushroom Enthusiasts Discover Two New Psilocybe Species
Fungi aficionados have reason to rejoice, as two new species of Psilocybe mushrooms – best known for their psychoactive properties – have been discovered in South Africa.

News
Potentially Safer MDMA Variants Identified for Psychotherapeutic Use
The use of the active ingredient 3,4-methylenedioxy-N-methylamphetamine (MDMA), commonly known as "ecstasy", to support psychotherapy for mental illnesses such as post-traumatic stress disorder is being discussed worldwide.

News
Slow-Release Ketamine Pill Reduces Severe Depression Symptoms, Study Finds
Research has found that a new tablet form of ketamine has shown promise in treating severe depression, offering a potential alternative to existing clinic-based treatments that can be expensive and lacking in convenience for some patients.
Advertisement